RANIHIGH SIGNALFINANCIAL10-K

RANI executed a major financial turnaround, eliminating going concern warnings while dramatically improving its balance sheet through what appears to be significant equity financing.

The removal of going concern language and substantial doubt about continuing operations represents a critical de-risking event for investors. The company appears to have successfully raised capital, evidenced by the massive increase in stockholders' equity and cash position, providing runway to continue operations and development programs.

Comparing 2026-03-26 vs 2025-03-31View on EDGAR →
FINANCIAL ANALYSIS

RANI experienced a dramatic financial transformation with stockholders' equity surging 1,557% to $33M and cash increasing 395% to $18.6M, clearly indicating successful equity fundraising. Operating cash flow burn improved significantly from -$35.5M to -$18.7M while total liabilities decreased 48%, demonstrating both improved cash management and debt reduction. The overall picture signals a company that has moved from financial distress to a substantially strengthened capital position, providing operational runway and removing immediate bankruptcy risk.

FINANCIAL STATEMENT CHANGES
Stockholders Equity
Balance Sheet
+1557.1%
$2.0M→$33.0M

Equity base grew 1557.1% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Cash & Equivalents
Balance Sheet
+394.9%
$3.8M→$18.6M

Cash position surged 394.9% — strong cash generation or capital raise providing significant financial cushion.

Current Assets
Balance Sheet
+79.3%
$29.7M→$53.3M

Current assets grew 79.3% — improving short-term liquidity or inventory/receivables build.

Capital Expenditure
Cash Flow
-67.2%
$268K→$88K

Capex reduced 67.2% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Total Assets
Balance Sheet
+60%
$36.6M→$58.6M

Asset base grew 60% — expansion through organic growth, acquisitions, or capital deployment.

Revenue
P&L
+58.9%
$1.0M→$1.6M

Strong top-line growth of 58.9% — accelerating demand or successful expansion into new markets.

Total Liabilities
Balance Sheet
-48.4%
$33.1M→$17.1M

Liabilities reduced 48.4% — deleveraging improves balance sheet strength and financial flexibility.

Operating Cash Flow
Cash Flow
+47.3%
-$35.5M→-$18.7M

Operating cash flow surged 47.3% — exceptional cash generation, highest quality earnings signal.

Interest Expense
P&L
-42.6%
$5.0M→$2.9M

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Current Liabilities
Balance Sheet
-36.3%
$19.9M→$12.7M

Current liabilities reduced — improved short-term financial position and working capital health.

LANGUAGE CHANGES
NEW — 2026-03-26
PRIOR — 2025-03-31
ADDED
As of February 28, 2026, the registrant ha d 99,721,927 shares of Class A common stock, $0.0001 par value per share, outstanding, 23,970,359 shares of Class B common stock, $0.0001 par value per share, outstanding and no shares of Class C common stock, $0.0001 par value per share, outstanding.
Certain holders of units of the registrant s consolidated subsidiary, Rani Therapeutics, LLC, who do not hold shares of the registrant s Class B common stock can exchange their units of Rani Therapeutics, LLC fo r 1,124,194 shares of the registrant s Class A common stock.
Management's Discussion and Analysis of Financial Condition and Results of Operations 99 Item 7A.
Our collaboration and license agreement with Chugai Pharmaceutical Co., Ltd.
may not be successful, and we may not realize the anticipated benefits of the collaboration.
+7 more — sign up free →
REMOVED
As of March 26, 2025, the registrant had 33,509,827 shares of Class A common stock, $0.0001 par value per share, outstanding, 23,971,852 shares of Class B common stock, $0.0001 par value per share, outstanding and no shares of Class C common stock, $0.0001 par value per share, outstanding.
Certain holders of units of the registrant s consolidated subsidiary, Rani Therapeutics, LLC, who do not hold shares of the registrant s Class B common stock can exchange their units of Rani Therapeutics, LLC for 1,229,630 shares of the registrant s Class A common stock.
Management's Discussion and Analysis of Financial Condition and Results of Operations 105 Item 7A.
There is substantial doubt regarding our ability to continue as a going concern.
We will need to raise additional funding, which may not be available on acceptable terms.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →